TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24041270
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection (405 mg/4 weeks, 300 mg/2 weeks, 150 mg/2 weeks)
Study: 24041270
Drug: Sub-therapeutic olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sub-therapeutic olanzapine long-acting injection (45 mg/4 weeks)
Study: 8883119
Drug: salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: salmon calcitonin nasal spray (CT; 200 IU/day, 1 month on and 1 month off) and calcium (500 mg/day)
Study: 8883119
Drug: calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium (500 mg/day)
Study: 3917316
Drug: Natural progesterone
Normalized name: NATURAL PROGESTERONE CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural progesterone given by mouth in increasing doses
Study: 27029823
Drug: Venetoclax 50
Normalized name: venetoclax 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax 50 mg (uncoated tablet)
Study: 27029823
Drug: Venetoclax film-coated
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax film-coated 100 mg tablet after low-fat breakfast
Study: 27029823
Drug: Venetoclax film-coated
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax film-coated 100 mg tablet after high-fat breakfast
Study: 12218282
Drug: Formulation D
Normalized name: Complete Formulation D3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation D
Study: 10589753
Drug: Paclitaxel 135
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 135 mg/m2, i.v., over a 3-h period, escalated to 175 and 200 mg/m2; Cisplatin 80 mg/m2, i.v., day 1; Etoposide 50 mg/m2, i.v., day 1 and 100 mg/m2 p.o., days 2-3 for the first group, then 80 mg/m2, i.v., day 1 and 160 mg/m2, p.o., days 2-3 for subsequent groups
Study: 7917734
Drug: 1% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% prilocaine 20 ml (plain)
Study: 7917734
Drug: 1% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% prilocaine 20 ml (alkalinized)
Study: 2973665
Drug: Nebulised ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised ipratropium 1 mg
Study: 2973665
Drug: Nebulised ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised ipratropium 1 mg at 6 am
Study: 29866475
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly carfilzomib (70 mg/m2)
Study: 29866475
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly carfilzomib (27 mg/m2)
Study: 29866475
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly carfilzomib
Study: 29866475
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly carfilzomib
Study: 28188155
Drug: Presentation framing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presentation framing the patient's absolute fracture risk as the chance of having or not having an event, with benefits from osteoporosis treatment in natural frequencies or numbers needed to treat.
Study: 12665996
Drug: Traditional flow
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional flow triggering (2 l/min)
Study: 4026908
Drug: Metoprolol 50
Normalized name: metoprolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50 mg twice daily
Study: 12167389
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg twice daily
Study: 10420109
Drug: Lomefloxacin 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin 0.3% eye drops twice daily
Study: 8828727
Drug: Fucidic acid
Normalized name: Fucidate
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fucidic acid 1% eye drops twice daily
Study: 1594263
Drug: Transdermal clonidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal clonidine, 0.3 mg/day
Study: 6510772
Drug: Liquid monopolar
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid monopolar - Storz (L)
Study: 31325145
Drug: Perifosine (PRF)
Normalized name: acetaminophen / phenyltoloxamine citrate Oral Tablet [Perisine]
DrugBank: Perifosine (DB06641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perifosine (PRF) 600 mg loading dose (4 divided doses on day 1) followed by 100 mg daily until disease progression or intolerable toxicity
Study: 29518077
Drug: Short term
Normalized name: Short Term Oral Swab System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short term psychodynamic therapy (PDT)
Study: 29518077
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) and Short term psychodynamic therapy (PDT)
Study: 26539836
Drug: Lidopat(®) 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidopat(®) 5% skin patch
Study: 26539836
Drug: Placebo vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vehicle patch
Study: 17376044
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (menatetrenone) at 45 mg per day
Study: 1954810
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg three times daily for 24 weeks
Study: 30860552
Drug: High-dose prenatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prenatal vitamin D supplementation
Study: 30860552
Drug: Standard-dose prenatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose prenatal vitamin D supplementation
Study: 27107153
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors as an alternative to tamoxifen with ovarian suppression
Study: 24521787
Drug: Inhaled hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled hypertonic saline solution (HSS)
Study: 22284962
Drug: Lack of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lack of periconceptional vitamins or supplements that contain folic acid
Study: 22284962
Drug: Periconceptional vitamins
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periconceptional vitamins or supplements that contain folic acid
Study: 17588826
Drug: Lovastatin 20-40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20-40 mg/day
Study: 12422101
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin injections
Study: 12422101
Drug: Both EPC
Normalized name: Epclusa
DrugBank: Velpatasvir (DB11613)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both EPC devices and unfractionated heparin injections
Study: 9854453
Drug: beta-blockers (metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blockers (metoprolol or propranolol)
Study: 7832192
Drug: rhGM-CSF with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM-CSF with prophylactic treatment with vitamin K
Study: 2170883
Drug: Yohimbine (alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (alpha 2‐adrenergic antagonist)
Study: 2170883
Drug: Clonidine (alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (alpha 2‐adrenergic agonist)
Study: 326219
Drug: Paracetamol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol + Caffeine (Finimal)
Study: 31813388
Drug: Drink containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink containing 700 mg of Ca (DAIR)
Study: 31813388
Drug: Energy-restricted diet
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-restricted diet containing 1200 mg Ca/d
Study: 31813388
Drug: Drink containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink containing 0 mg of Ca (CONT)
Study: 30537063
Drug: Topical cysteamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cysteamine cream applied once daily for 2 and 4 months.
Study: 30537063
Drug: Topical cysteamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cysteamine cream applied biweekly after initial treatment.
Study: 30537063
Drug: Topical cysteamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cysteamine cream.
Study: 26116930
Drug: Lisdexamfetamine (LDX)
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine (LDX) 70 mg
Study: 26116930
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) 0 mg
Study: 21830062
Drug: Initial CPAP
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial CPAP treatment in OSAS group
Study: 17489880
Drug: NPD +
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NPD + L-phenylalanine (7.5 g/day)
Study: 17489880
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (HPD, 141.3 +/‐ 3.7 g/day)
Study: 17489880
Drug: Normal-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-protein diet (NPD, 73.2 +/‐ 2.6 g/day)
Study: 11413085
Drug: Co-amilozide (hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amilozide (hydrochlorothiazide 25 mg and amiloride 2.5 mg)
Study: 9626118
Drug: Diazoxide (DZ)
DrugBank: Diazoxide (DB01119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazoxide (DZ) 2 mg/kg BW.day; maximum 200 mg/day, divided into 3 doses for 8 weeks
Study: 7701041
Drug: Nicotine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (0, 2, 4, 8, and 12 micrograms/kg) administered by measured‐dose nasal spray
Study: 7701041
Drug: Nicotine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (12 micrograms/kg) administered by measured‐dose nasal spray
Study: 30222788
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous (IV) and intra-articular (IA) administration of tranexamic acid (TXA)
Study: 30222788
Drug: IV only
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV only administration of tranexamic acid (TXA)
Study: 30222788
Drug: Combined IV
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined IV and IA administration of TXA
Study: 30222788
Drug: IV only
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV only administration of TXA
Study: 23436914
Drug: Atorvastatin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin for 36 months
Study: 22512878
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal amino acid solution in the same quantity for 7 days)
Study: 20227716
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (15 mg zinc + 60 mg iron + 250 microg folic acid)
Study: 20227716
Drug: Placebo (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (60 mg iron + 250 microg folic acid)
Study: 15795200
Drug: Ultrasound-guided needling
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided needling followed by high-energy shock-wave therapy
Study: 15795200
Drug: Shock-wave therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock-wave therapy alone
Study: 12493263
Drug: Fosmidomycin for
Normalized name: fosfomycin Granules for Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosmidomycin for 5 days (1.2 g every 8 h)
Study: 12493263
Drug: Fosmidomycin for
Normalized name: fosfomycin Granules for Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosmidomycin for 4 days (1.2 g every 8 h)
Study: 12493263
Drug: Fosmidomycin for
Normalized name: fosfomycin Granules for Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosmidomycin for 3 days (1.2 g every 8 h)
Study: 10909495
Drug: Program I
Normalized name: Program Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program I (individual, motivating instructions of oral cavity hygiene, 10 meetings)
Study: 2387655
Drug: SMS 201-995
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS 201-995 (10-hour i.v. infusion at a rate of 8 g/min)
Study: 30900268
Drug: Energy-enriched formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-enriched formula (EE-formula) (1 kcal/mL)
Study: 30900268
Drug: Normocaloric formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normocaloric formula (0.67 kcal/mL)
Study: 31084562
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) applied three times a week for 4 weeks
Study: 31084562
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) applied once a week for 4 weeks
Study: 27813150
Drug: Cariex® spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariex® spray combined with non-surgical periodontal therapy
Study: 27813150
Drug: Cariex® spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariex® spray alone
Study: 27813150
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy alone
Study: 25530011
Drug: Boysenberry beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boysenberry beverage (750 mg polyphenols)
Study: 25530011
Drug: Apple fiber
Normalized name: Acacia/Apple Fiber/Apple Pectin/Astragalus Root/Barberry Bark/Beet Root/Burdock Root/Capsicum/Ginger Root/Milk Thistle Seed Extract/Peppermint Leaf Extract/Prune/Psyllium Husk/Watercress Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple fiber beverage (7.5 g dietary fiber)
Study: 25530011
Drug: Boysenberry plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boysenberry plus apple fiber beverage (750 mg polyphenols plus 7.5 g dietary fiber)
Study: 25146288
Drug: No vaccine
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vaccine (Control)
Study: 22520095
Drug: CTC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC group (CT cisternography considered before treatment)
Study: 14727868
Drug: Liposomal tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal tretinoin (TRE) and benzoyl peroxide (BP) gels
Study: 8070509
Drug: Oral lomefloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lomefloxacin 200 mg with furosemide 40 mg
Study: 8070509
Drug: Oral lomefloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lomefloxacin 200 mg alone
Study: 8070509
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg alone
Study: 3123119
Drug: Complete intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete intravenous nutritional support (IVF) with all D‐glucose
Study: 3123119
Drug: Complete intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete intravenous nutritional support (IVF) with 50% D‐glucose/50% lipid
Study: 3123119
Drug: Complete intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete intravenous nutritional support (IVF) with D‐glucose/amino acid regimen
Study: 3123119
Drug: Complete intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete intravenous nutritional support (IVF) with D‐glucose/lipid/amino acid regimen
Study: 20406831
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (NT) including epirubicin/cyclophosphamide followed by docetaxel alone, docetaxel with capecitabine, or docetaxel followed by capecitabine, with additional trastuzumab treatment for HER2-positive tumors.
Study: 20406831
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (NT) with trastuzumab for HER2-positive tumors.
Study: 20406831
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (NT) with no specific control mentioned.
Study: 18242480
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with carvedilol and amiodarone
Study: 2903425
Drug: CV 205‐502
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV 205‐502 (0.01 to 0.09 mg single oral doses)
Study: 2903425
Drug: CV 205‐502
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV 205‐502 (0.06 mg single oral dose)
Study: 26573323
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Treatment (MET)
Study: 26573323
Drug: Compliance with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliance with treatment (secondary outcome)
Study: 19638080
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (nadolol plus isosorbide‐5‐mononitrate)
Study: 19638080
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group (banding ligation plus medications)
Study: 15108863
Drug: 2% clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% clindamycin vaginal cream (CVC)
Study: 11117277
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day of lycopene (LYC‐O‐MATO)
Study: 9494599
Drug: ABVD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVD chemotherapy followed by mediastinal irradiation at a median dose of 36 Gy (range 30.6‐43.2)
Study: 30011303
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and alternative medicine (CAM) usage
Study: 25944813
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dexketoprofen in 50 ml saline
Study: 25944813
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml saline as placebo
Study: 23206408
Drug: Low-dose Cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Cyclosporine A (trough concentrations 130 < CsA < 200 μg/L, n=47)
Study: 23206408
Drug: Standard-dose Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose Cyclosporine A (trough concentrations 200 < CsA < 300 μg/L, n=48)
Study: 18608200
Drug: Valsartan vs
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan vs Amlodipine (Treatment Benefit)
Study: 10903213
Drug: Cylexin (CY-1503)
Normalized name: Cys
DrugBank: Cysteine (DB00151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cylexin (CY-1503) administered on the day of surgery
Study: 9071250
Drug: Telephone-based problem-solving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based problem-solving therapy sessions conducted by graduate student therapists supervised by a psychiatrist.
Study: 24356922
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone plus intravenous acetaminophen
Study: 24356922
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine sulfate
Study: 23042034
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (onabotulinumtoxinA) injection (160 U) into biceps brachii
Study: 23042034
Drug: Before injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before injection
Study: 19503784
Drug: Degarelix (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degarelix (240 mg initial dose followed by 80 mg or 160 mg monthly injections)
Study: 28427285
Drug: Leuprolide (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide (GnRH agonist)
Study: 11220888
Drug: Quadropril (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadropril (6 mg once daily)
Study: 11220888
Drug: Amlodipine (initially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (initially 5 mg/day, increased to 10 mg/day if necessary)
Study: 9750602
Drug: Intramuscular ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular ephedrine 30 mg immediately after SB
Study: 9750602
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL of intramuscular saline) immediately after SB
Study: 8458358
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Nifedipine + Propranolol)
Study: 3797826
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral nifedipine
Study: 14584565
Drug: FDG uptake
Normalized name: (18F)-FDG
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG uptake ratios with occipital lobe metabolism as covariate reference region
Study: 14584565
Drug: FDG uptake
Normalized name: (18F)-FDG
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG uptake ratios with white matter metabolism as reference covariate
Study: 10712324
Drug: Intravenous augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous augmentation therapy
Study: 8689423
Drug: Low-dose cytosine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytosine arabinoside (LD AraC) 2 x 10 mg/m2 sc, day 1-14 plus interleukin-3 (IL-3) once daily sc, day 8-21 at varying doses (1.0, 2.5, 5.0, and 10.0 micrograms/kg)
Study: 31856049
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (placebo group)
Study: 29137628
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (HS) pre-injection 4 mL/kg 7.5% HS
Study: 29137628
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (HS) pre-injection